This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Adu, D Articles by Jayne, D R. Search for Related Content PubMed PubMed Citation Articles by Adu, D Articles by Jayne, D R. Social Bookmarking                         What's this?

Treatment of systemic lupus erythematosus with mycophenolate mofetil

Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK dwoms{at}aol.com

J Cross

D RW Jayne

Division of Renal Medicine, St George's Hospital Medical School and Renal Unit, and St Helier Hospital, London, UK

Mycophenolate mofetil is an immunosuppressive drug that is of established efficacy in renal transplantation. It inhibits the de novo pathway of purine synthesis and therefore lymphocyte proliferation. Mycophenylate mofetil has been shown to ameliorate the severity of renal injury in murine models of lupus nephritis. Recent studies suggest that it may also be effective in the treatment of patients with lupus nephritis when used in conjunction with steroids. These observations need to be confirmed in adequately sized randomised-controlled studies.

Key Words: lupus • nephritis • mycophenolate mofetil • treatment

Lupus, Vol. 10, No. 3, 203-208 (2001)
DOI: 10.1191/096120301673517315


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Y. Karim, C. N. Pisoni, and M. A. Khamashta Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not! Rheumatology, April 1, 2009; 48(4): 332 - 341. [Abstract] [Full Text] [PDF]

				M R Wilkins and J K G Dart Mycophenolate mofetil for the treatment of severe inflammatory external eye diseases Br J Ophthalmol, April 1, 2008; 92(4): 578 - 579. [Full Text] [PDF]

				C. N. Pisoni, M. J. Cuadrado, M. A. Khamashta, G. R. V. Hughes, and D. P. D'Cruz Mycophenolate mofetil treatment in resistant myositis Rheumatology, March 1, 2007; 46(3): 516 - 518. [Abstract] [Full Text] [PDF]

				M. Y. Karim, C. N. Pisoni, L. Ferro, M. F. Tungekar, I. C. Abbs, D. P. D'Cruz, M. A. Khamashta, and G. R. V. Hughes Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy Rheumatology, October 1, 2005; 44(10): 1317 - 1321. [Abstract] [Full Text] [PDF]

				H Guo, J C. Leung, L Y. Chan, S L Lui, A W. Tsang, and K N Lai Modulation of intra-pulmonary TGF-b expression by mycophenolate mofetil in lupus prone MRL/lpr mice Lupus, August 1, 2005; 14(8): 583 - 592. [Abstract] [PDF]

				C. Lagaraine, C. Hoarau, V. Chabot, F. Velge-Roussel, and Y. Lebranchu Mycophenolic acid-treated human dendritic cells have a mature migratory phenotype and inhibit allogeneic responses via direct and indirect pathways Int. Immunol., April 1, 2005; 17(4): 351 - 363. [Abstract] [Full Text] [PDF]

				C N Pisoni, Y Karim, and M J Cuadrado Mycophenolate mofetil and systemic lupus erythematosus: an overview Lupus, March 1, 2005; 14(3_suppl): s9 - s11. [Abstract] [PDF]

				M Y Karim and I C Abbs Mycophenolate mofetil in nonlupus glomerulonephropathy Lupus, March 1, 2005; 14(3_suppl): s39 - s41. [Abstract] [PDF]

				M Hartmann and A Enk Mycophenolate mofetil and skin diseases Lupus, March 1, 2005; 14(3_suppl): s58 - s63. [Abstract] [PDF]

				C. Pisoni, Y. Karim, and M. Cuadrado Mycophenolate mofetil and systemic lupus erythematosus: an overview Lupus, January 1, 2005; 14(1_suppl): s9 - s11. [Abstract] [PDF]

				M. Karim and I. Abbs Mycophenolate mofetil in nonlupus glomerulonephropathy Lupus, January 1, 2005; 14(1_suppl): s39 - s41. [Abstract] [PDF]

				M. Hartmann and A. Enk Mycophenolate mofetil and skin diseases Lupus, January 1, 2005; 14(1_suppl): s58 - s63. [Abstract] [PDF]

				Y Karim and D P D'Cruz The NIH pulse cyclophosphamide regime: the end of an era? Lupus, January 1, 2004; 13(1): 1 - 3. [PDF]

				C. J. Day, P. Cockwell, G. W. Lipkin, C. O. S. Savage, A. J. Howie, and D. Adu Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome Nephrol. Dial. Transplant., November 1, 2002; 17(11): 2011 - 2013. [Abstract] [Full Text] [PDF]

				M. Y. Karim, P. Alba, M.-J. Cuadrado, I. C. Abbs, D. P. D'Cruz, M. A. Khamashta, and G. R. V. Hughes Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents Rheumatology, August 1, 2002; 41(8): 876 - 882. [Abstract] [Full Text] [PDF]

				C L Teh, K O Kong, A P. Chong, and H Badsha Mycobacterium haemophilum infection in an SLE patient on mycophenolate mofetil Lupus, April 1, 2002; 11(4): 249 - 252. [Abstract] [PDF]